156 related articles for article (PubMed ID: 21902077)
1. The NHS: assessing new technologies, NICE and value for money.
Stevens A; Chalkidou K; Littlejohns P
Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
[TBL] [Abstract][Full Text] [Related]
2. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
3. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
4. Can the NICE "end-of-life premium" be given a coherent ethical justification?
Cookson R
J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
[TBL] [Abstract][Full Text] [Related]
5. The NHS: assessing new technologies, NICE and value for money.
Patel M
Clin Med (Lond); 2011 Oct; 11(5):508; author reply 508-9. PubMed ID: 22034723
[No Abstract] [Full Text] [Related]
6. The role of health economics in the evaluation of surgery and operative technologies.
Taylor M
Surgery; 2017 Feb; 161(2):300-304. PubMed ID: 28096035
[TBL] [Abstract][Full Text] [Related]
7. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
8. [The National Institute for Clinical Excellence (NICE)].
Rothgang H; Niebuhr D; Wasem J; Gress S
Gesundheitswesen; 2004 May; 66(5):303-10. PubMed ID: 15141350
[TBL] [Abstract][Full Text] [Related]
9. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
10. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
11. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
12. Clinical Guidelines: A NICE Way to Introduce Cost-Effectiveness Considerations?
Drummond M
Value Health; 2016; 19(5):525-30. PubMed ID: 27565268
[TBL] [Abstract][Full Text] [Related]
13. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
14. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
15. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
16. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
17. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
Birch S; Gafni A
Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
[No Abstract] [Full Text] [Related]
18. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
20. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
